Sleep Walking1

You might also like

Download as pdf or txt
Download as pdf or txt
You are on page 1of 8

General Hospital Psychiatry 65 (2020) 74–81

Contents lists available at ScienceDirect

General Hospital Psychiatry


journal homepage: www.elsevier.com/locate/genhospsych

Review article

Sleepwalking and sleep-related eating associated with atypical antipsychotic T


medications: Case series and systematic review of literature

Amit Chopraa, , Rikinkumar S. Patelb, Nisha Baligac, Anoop Naraharid, Piyush Dase
a
Psychiatry and Behavioral Health Institute, Department of Sleep Medicine, Allegheny Health Network, Pittsburgh, PA, United States
b
Department of Psychiatry, Griffin Memorial Hospital, Norman, OK, United States
c
Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States
d
Psychiatry and Behavioral Health Institute, Allegheny Health Network, Pittsburgh, PA, United States
e
Department of Sleep Medicine, CentraCare, MN, United States

A R T I C LE I N FO A B S T R A C T

Keywords: Background: Sleep walking (SW) is a parasomnia behavior characterized by repetitious occurrence of ambula-
Atypical antipsychotics tion during a partial arousal from non-rapid eye movement (NREM) sleep. Sleep-related eating (SRE) is one of
Sleep walking the complex sleep behaviors that may accompany SW. Emerging evidence suggests that NREM parasomnias can
Sleep-related eating be associated with atypical antipsychotic medication use.
Parasomnias
Methods: We present a case series (n = 5) and a systematic review of the literature of cases of SW, with or
Weight gain
without SRE (n = 23), associated with atypical antipsychotic use.
Results: Twenty-eight cases of SW, with and without SRE, with a mean age of 44.8 years (S.D. = 15.04) and a
male predominance (75%; n = 21) were identified. Quetiapine was the most commonly implicated medication
with SW and SRE (n = 14). Remission from SW/SRE was noted in all cases with measures including anti-
psychotic dosage reduction, discontinuation of medication, switching to an alternate medication, and use of
continuous positive airway pressure (CPAP) for comorbid obstructive sleep apnea (OSA) treatment.
Conclusions: Sleep walking (SW), with or without sleep related eating (SRE), can be a rare but reversible side
effect associated with use of atypical antipsychotics. More research is warranted to elucidate the mechanisms
underlying SW and SRE associated with atypical antipsychotic use.

1. Introduction childhood. SW occurs in 1.5% of adults, however, with roughly 80% of


these cases having a continuation of childhood behavior [3,4]. The
Parasomnias are a group of disorders that are characterized by ab- prevalence is noted to be the greatest between three to ten years of age
normal behavioral, experiential or physiological events that occur in and typically resolves by adolescence [5] thus indicating that first
association with sleep, specific sleep stages, or sleep-wake transitions episode of sleepwalking is rare in adults. This also suggests that if SW
[1]. These can be classified as either non-rapid eye movement (NREM) happens for the first time in adulthood, there must be an extrinsic factor
or rapid eye movement (REM) parasomnia depending on the sleep stage triggering it like a new disease or medication which did not exist during
from which they arise. According to the Diagnostic and Statistical the childhood.
Manual of Mental Disorders, 5th Edition (DSM-5), NREM parasomnias Sleep related eating (SRE) is one of the complex behaviors that may
are classified into two major types- sleepwalking (SW) and sleep terrors. accompany sleep walking. SRE is characterized by recurrent episodes of
SW is characterized by repetitive occurrence of ambulation while involuntary eating and drinking that occur during partial arousal from
sleeping triggered by a partial arousal during stage N3 sleep usually in NREM sleep [6]. SRE is a unique behavior seen during SW which tends
the first half of sleep period [2]. The partial arousals may be sponta- to appear for the first time during early adulthood [7]. With the lifetime
neous or result from sleep disruptors like apneas/hypopneas or periodic prevalence of 4.5%, current prevalence (in the last three months) of
limb movements. SW occurs with open eyes, has potential for injury to 2.2%, and current prevalence (at least once per week) of 0.4%, it is
self and others, can result in violence if interrupted, and ends sponta- most commonly associated with primary sleep, medical, and psychiatric
neously without full awakening. SW has a prevalence rate of 5% in disorders including restless legs syndrome (RLS), periodic limb


Corresponding author.
E-mail addresses: Amit.CHOPRA@ahn.org (A. Chopra), Nisha.P.Baliga@hitchcock.org (N. Baliga), anoop.narahari@ahn.org (A. Narahari),
Piyush.Das@centracare.com (P. Das).

https://doi.org/10.1016/j.genhosppsych.2020.05.014
Received 21 January 2020; Received in revised form 22 May 2020; Accepted 31 May 2020
0163-8343/ © 2020 Elsevier Inc. All rights reserved.

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

movement disorder (PLMD), obstructive sleep apnea (OSA), narcolepsy, “lurasidone” or “asenapine”. Case reports and case series were con-
circadian rhythm sleep-wake disorders (particularly irregular sleep/ sidered for analysis and all abstracts and titles were examined by two
wake type), autoimmune hepatitis, encephalitis, eating disorders, and independent reviewers (A.C. and R.P.).
nocturnal dissociative disorder [7].
The patients may engage in involuntary eating and drinking during 3. Results
these occurrences with no or just partial recollection of SW or SRE upon
awakening. SRE is characterized by ingestion or consumption of aty- 3.1. Patient characteristics
pical foods, inedible or toxic substances (e.g., frozen pizzas, raw bacon,
buttered cigarettes, cat food and salt sandwiches, coffee grounds, am- Based on our case series and the review of literature, we found a
monia cleaning solutions); sleep related injury can result from careless total of twenty three published cases and five unpublished cases in our
manipulation of kitchen utensils, consuming or spilling hot foods or outpatient clinic (n = 28) of sleep walking (SW), with or without sleep-
beverages, eating foods one is allergic to and ingesting toxic substances. related eating (SRE), that were associated with atypical antipsychotic
Other possible adverse health consequences include dental caries and use. The mean age of patients was 44.8 years (S.D. = 15.04) and a male
tooth chipping from biting frozen foods, weight gain, obesity, various predominance (75%; n = 21) was noted. The majority of the SW/SRE
metabolic problems such as destabilization or precipitation of diabetes episodes occurred in patients aged 51–60 years (32.1%, n = 9), and
mellitus, hypertriglyceridemia and hypercholesterolemia, non- 41–50 and 18–30 years (21.4%, each). More than half of the patients
restorative sleep from sleep disruption, morning anorexia, abdominal with SW (53.6%, n = 15) also presented with SRE. About 75% (n = 21)
distention, depression and insomnia [7]. patients were amnestic to events upon awakening. Demographic and
Many different classes of medications have been implicated in SW clinical characteristics of the patients with SW/SRE associated with
during adulthood with the strongest association being noted with the atypical antipsychotic use are described in Table 1.
use of zolpidem use [8–12]. Other medications less commonly im- The majority of the SW/SRE episodes associated with atypical an-
plicated in emergence of SW during adulthood include other hypnotics tipsychotics were associated with use of quetiapine (50%; n = 14),
(zaleplon [13,14], zopiclone [8,15]), antidepressants (amitriptyline followed by olanzapine (25%; n = 7), risperidone (10.7%, n = 3), and
[16], paroxetine [17], fluoxetine [18], sertraline [17], mirtazapine aripiprazole (10.7%, n = 2), ziprasidone, and asenapine (3.6% each).
[19], reboxetine [20] and bupropion [21]), mood stabilizers (lithium Bipolar disorder type-I and type II, and schizophrenia (21.4% each)
[22–25]), first generation antipsychotics (chlorprothixene [26], per- constituted major proportions of patients with SW. However, SW with
phenazine [26] and thioridazine [26,27]), beta blockers (propranolol SRE was most prevalent in bipolar disorder type-I (n = 4; 26.7%) fol-
[28–30] and metoprolol [31,32]), and miscellaneous drugs (cipro- lowed by major depressive disorder and bipolar disorder type-II (20%
floxacin [33], bromocriptine [34], methylphenidate [35], suvorexant each). Quetiapine (n = 8, 53.3%) followed by aripiprazole and risper-
[36], sodium oxybate [37], varenicline [38] and montelukast [39]). idone (13.3% each) were most commonly implicated atypical anti-
SRE has also been associated with the use of sedative-hypnotic medi- psychotics in patients presenting with SW with SRE.
cations including benzodiazepine receptor agonists (zolpidem), mirta-
zapine, lithium, anticholinergics, and various other psychotropic agents 3.2. Clinical characteristics and outcomes
[7,40]. A recent systematic review illustrated that there is significantly
elevated rates of parasomnias (including SW and SRE) in psychiatric Majority of the SW events, with or without SRE, were associated
disorders with use of psychotropic medications being implicated as the with use of quetiapine (n = 14, 50%). Among the patients with SW
major cause of parasomnias in this population [41]. episodes associated with quetiapine use, 57.1% (n = 8) of the patients
Use of atypical antipsychotics has been steadily increasing across reported SRE [25,44–47] and about half (n = 6, 50%) of them had
the world for a range of clinical indications including schizophrenia, associated parasomnia which ranged from leg jerks, jumping from bed,
schizoaffective disorder, bipolar disorder, and major depression with property destruction, manipulating belongings and assaults to family
quetiapine, risperidone, and olanzapine being the most frequently members [25,45,47]. In four cases, quetiapine was discontinued and
prescribed antipsychotic medications across 16 countries in an inter- switched to a different antipsychotic [44–46], in three cases the dose
national study [42]. The atypical antipsychotic medications are asso- was tapered [45,47] and other three cases the medication was dis-
ciated with lesser incidence of extrapyramidal side effects (EPSE) and continued [25,45,48]. Olanzapine was noted to be second most com-
tardive dyskinesia; however, these medications have substantial meta- monly implicated atypical antipsychotic with seven patients presenting
bolic side effects leading to insulin resistance, weight gain and obesity with SW including one patient reporting SRE associated with SW [49].
[43]. While various reasons have been cited for weight gain associated Approximately 66.7% (n = 4) of patients taking olanzapine also pre-
with atypical antipsychotic medication therapy, SW with SRE may be sented with complex behaviors including head banging, trying to
one of the rare but under-recognized reasons. throttle other members, relocating clothes/belongings, talking loud and
In this paper, we present five clinical cases of SW, with or without urinate at bedside [49–52]. In three cases olanzapine was switched to
SRE, and also systematically analyze the current literature to review the another medication (aripiprazole [52] and risperidone [53]); in one
clinical presentation, risk factors, and management of these parasomnia case the dose of olanzapine was reduced [51]; and in three cases this
behaviors associated with atypical antipsychotic use in psychiatric pa- medication was discontinued [48–50]. Remission was seen in all six
tients (Fig. 1) [76]. cases of olanzapine induced SW/SRE. Additionally, SW with SRE was
noted in two patients taking aripiprazole and remission of these para-
2. Methods somnia behaviors was seen after switching the medication.
Three patients on risperidone reported SW and out of them two
We conducted a systematic review of the literature based on the reported associated SRE [54–56]. The dose of risperidone was tapered
guidelines by Preferred Reporting Items for Systematic Reviews and down in all cases [54–56], with no improvement and so discontinued in
Meta-Analysis (PRISMA) statement [Fig. 1]. one case [54], whereas in another case it was managed by continuing
MEDLINE database was searched from April 1996 to March 2017 for lower dose of risperidone with clonazepam 0.5 mg daily [55]. One
English language case reports and case series on the topic of SW and patient taking ziprasidone reported SW associated with SRE and para-
SRE associated with atypical antipsychotic use. We used search terms: somnia including cooking food without recollection of such events next
“sleep walking” or “sleep-related eating” or “somnambulism” and morning. As a part of management of SW with SRE, ziprasidone 40 mg
“olanzapine” or “clozapine” or “quetiapine” or “risperidone” or “ilo- QAM (daily morning) was continued and ziprasidone 80 mg QHS (daily
peridone” or “paliperidone” or “ziprasidone” or “aripiprazole” or bed time) was switched to quetiapine 100 mg QHS with remission seen

75

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

Identification
Records idenfied through
MEDLINE database searching
(n = 35)
Screening

Records screened
(n = 35)

Full-text arcles excluded


(n=20) with reasons-
text unavailable, safety
Full-text arcles assessed reviews, cross-seconal
for eligibility
Eligibility

studies, systemac reviews,


(n = 35) arcles on night eang
syndrome, combinaon of
medicaons

Studies included in
Included

qualitave synthesis
(n = 15)

Fig. 1. PRISMA Flowsheet

in two months [57]. One patient taking asenapine 15 mg daily for bi- reported having recurrent episodes of SW with SRE associated with
polar 1 disorder presented with SW associated with SRE [48] and these choking during sleep and weight gain after quetiapine was initiated for
symptoms resolved immediately after the discontinuation of asenapine. mood stabilization. He reported weight gain secondary to SRE. He re-
None of the patients treated with olanzapine, risperidone and zi- ported having little awareness of his SW and SRE. Clinical history was
prasidone had a past or family history of SW. On the contrary, one essentially negative for obstructive sleep apnea (OSA) and patient was
patient taking quetiapine had a past history of SW associated with use at low pre-test probability for OSA. His medical and neurological his-
of zolpidem 10 mg QHS [45] and another patient had a strong family tory was essentially negative except for chronic back pain. There was a
history of SW [45]. A patient taking asenapine had a past history of SW brief emergence of RLS after initiation of quetiapine which responded
associated with use of olanzapine 15 mg daily and quetiapine 600 mg well to short-term use of pramipexole with no resurgence of restless legs
daily [48]. Clinical features and the management of SW, with or symptoms subsequently. However, there was persistence of SW and SRE
without SRE, associated with use of atypical antipsychotics are sum- with continuous use of quetiapine. He reported having a past history of
marized from the published cases (n = 23) in Table 2. multiple episodes of depression and hypomania, but felt the current
medication regimen including quetiapine was superior to other medi-
cation trials for mood stabilization.
3.3. Unpublished cases in an outpatient setting
Topiramate was initiated at 25 mg QHS that was further titrated to
50 mg QHS over 4 weeks to control SW with SRE. He responded well to
We report four cases of SW with SRE and one case of SW in psy-
topiramate trial with complete resolution of SW and SRE; un-
chiatric patients that were associated with the use of atypical anti-
fortunately, he developed adverse drug reactions (ADRs) including
psychotics in the outpatient sleep and psychiatry clinics at Allegheny
cognitive dysfunction and hair loss. Topiramate had to be discontinued
Health Network.
because of ADRs which resulted in relapse of SW and SRE. Patient was
unwilling to discontinue quetiapine due to its unparalleled efficacy as a
Case 1:
mood stabilizer. Due to documented efficacy of benzodiazepines in the
treatment of parasomnias, alprazolam 1.5 mg QHS was initiated with an
A 47-year-old married Caucasian male with bipolar disorder type II,
excellent response and complete resolution of SW and SRE symptoms.
rapid cycling in nature, obsessive compulsive disorder and attention
deficit hyperactivity disorder was on treatment with divalproex sodium
Case 2:
2000 mg QHS, quetiapine 300 mg QHS, duloxetine 120 mg daily and
dextroamphetamine/amphetamine 20 mg TID (three times daily). He

76

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

Table 1 polysomnography and for narcolepsy on multiple sleep latency test.


Demographic characteristics of patients with sleep walking (SW), with or
without sleep-related eating (SRE), both published and unpublished cases Case 4:
(n = 28).
Variable Cases (N) Proportion (%) A 26-year old single Asian male with history of Kleine-Levin syn-
drome (KLS) and major depressive disorder (MDD), who developed SW
Age
with SRE after initiation of aripriprazole for treatment of severe de-
18–30 years 6 21.4
31–40 years 3 10.7
pression. He was initially evaluated in the sleep clinic for complaints of
41–50 years 6 21.4 hypersomnia and sleep work-up unremarkable for sleep apnea and
51–60 years 9 32.1 narcolepsy. He had unsuccessful trials of modafinil, armodafinil, and
61–70 years 3 10.7 methylphenidate for management of hypersomnia. Patient endorsed
> 70 years 1 3.6
severely depressed mood for one year in the context of break up with
Gender girl-friend. He displayed symptoms of KLS such as hypersomnia
Male 21 75.0
(sleeping for three days, cognitive dysfunction, hyperphagia and hyper-
Female 7 25.0
sexuality). KLS symptoms first started when he was in high school,
Psychiatric diagnosis
decreased in frequency over the course of years. Sertarline was initiated
Schizophrenia 6 21.4
Bipolar disorder II 6 21.4
and titrated to 100 mg daily and aripiprazole 2 mg was subsequently
Bipolar disorder I 6 21.4 added due to suicidal depression. He noted a significant improvement
Major depressive disorder 5 17.9 in his mood and felt less sleepy with addition of aripiprazole. He
Schizoaffective disorder 2 7.1 wanted to continue aripiprazole despite noticing 30 lbs. weight gain
Psychotic disorder due to Vascular dementia 1 3.6
due to insatiable appetite as reason for weight gain. He was started on
ADHD 1 3.6
Conduct disorder 1 3.6 topiramate 50 mg BID (twice daily) for binge eating behaviors and
migraine prophylaxis due to history of migraines. Topiramate was in-
Antipsychotics
Quetiapine 14 50.0 effective in controlling weight gain and he gained 70 lbs. weight over
Olanzapine 7 25.0 six month period despite exercising and modifying his diet. On detailed
Aripiprazole 2 7.1 questioning, he reported that he may have been eating large amounts of
Ziprasidone 1 3.6 food without having any conscious awareness of his eating episodes.
Asenapine 1 3.6
For example, he found pizza boxes next to him which were ordered by
Risperidone 1 10.7
him during the day time. He did not remember either calling for food or
eating the food. He denied such eating behaviors as characteristic of
A 37-year-old married African-American female with bipolar dis- KLS and he was distinctly able to distinguish between SRE and ab-
order type I, rapid cycling, panic disorder and obsessive-compulsive normal eating behaviors due to KLS. Metabolic testing revealed fasting
disorder who was treated with quetiapine 300 mg QHS, lamotrigine 100 glucose to be in normal range, however, lipid panel showed moderate
mg daily, and clonazepam 1 mg QHS. Her medical and neurological elevation in LDL. Aripiprazole was stopped and he was placed on
history was negative, and she had no prior history of eating disorders. Wellbutrin XL 150 mg daily in addition to sertraline. Complete resolu-
She experienced SW with SRE after initiation of quetiapine but due to tion of SRE episodes was noted with cessation of aripiprazole treatment
sporadic nature of these events, she initially did not report these and symptoms never recurred upon long term outpatient follow-up.
symptoms. When the dose of quetiapine was subsequently increased to
300 mg daily, she reported significant increase in SW with SRE. She was Case 5:
incognizant of these episodes, which she found most troublesome. She
reported an increase in her weight due to SRE. Her metabolic profile A 41-year-old married Caucasian male, receiving rehabilitation for
including HbA1c and lipid profile were within normal limits. Sleep post-concussion syndrome, was referred to sleep clinic for complaints of
history was suggestive of low-risk for obstructive sleep apnea (OSA), insomnia. He was on venlafaxine 225 mg for headaches and anxiety at
absence of restless legs syndrome and prior parasomnia and eating time of initial presentation. Previous failed trials include sertraline,
disorders. Quetiapine was subsequently discontinued due to intolerable clonazepam, amantadine, amitriptyline, prazosin and zolpidem for
side effects such as parasomnias and significant weight gain. Complete anxiety, insomnia and PTSD symptoms. He was started on low dose of
resolution of SW with SRE was noted upon discontinuation of quetia- trazodone, which was discontinued due to worsening headaches at a
pine and initiation of risperidone 2 mg QHS for mood stabilization. higher dose of 75 mg. After he was started on quetiapine 50 mg QHS for
management of insomnia, he began to experience symptoms of sleep-
Case 3: walking. He had approximately six episodes of sleepwalking before he
decided to come off of this medication; after discontinuation, these
A 19-year-old single Caucasian male, with a medical history of type- adverse effects quickly resolved. No history suggestive of OSA and
1 diabetes mellitus, unsuccessful trials with multiple antidepressants for restless legs was evident. No prior history of parasomnia behaviors was
a mood disorder, presented to sleep clinic with complaints of initial reported. He was resumed on trazodone 50 mg QHS and referred to
insomnia and daytime hypersomnia. His medication regimen included trauma focused- cognitive behavioral therapy for PTSD as nightmares
aripriprazole 10 mg QHS and trazodone 100 mg QHS at the time of related to head injury were interfering with sleep maintenance.
initial presentation. He was experiencing episodes of sleep related
eating approximately two years. Psychiatric assessment revealed cyclic 4. Discussion
mood patterns including depression and week long periods of hypo-
mania. He was diagnosed with bipolar disorder, rapid cycling, and ar- The incidence of SW, with or without SRE, in context of atypical
ipiprazole was switched to lithium. The patient had significant im- antipsychotic use seemed to be anecdotal in nature initially; however,
provement in insomnia and sleep related eating completely resolved the growing literature on this topic merits further scientific inquiry. The
upon discontinuation of aripriprazole. Patient also had complaints of aim of our study was to review the literature to identify the risk factors
restless legs during nighttime, and some gasping episodes. However, and clinical correlates that may be associated with causation of SW,
sleep workup was unremarkable; negative for sleep apnea on with or without SRE, in patients taking atypical antipsychotic medica-
tions. This is particularly important and timely as these medications are

77

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

Table 2
Summary of clinical features and outcomes of sleep walking (SW), with or without sleep-related eating (SRE), associated with use of atypical antipsychotics of
published cases from literature (n = 23).
Study N Age (years) Gender Diagnosis Antipsychotic Clinical Characteristics Treatment Remission

Das et al., 2016 1 28 Male Schizoaffective Disorder Ziprasidone 40 mg SW and SRE Ziprasidone 80 mg QHS Yes; in 2 months
QAM Parasomnia switched to quetiapine 100
Ziprasidone 80 mg Amnesia of SW episode mg QHS
QHS
Das et al., 2017 1 26 Male Schizophrenia Olanzapine 15 mg SW and SRE Olanzapine switched to Yes; in 2 months
daily Parasomnia aripiprazole
Amnesia of SW episode
Episode lasts for
10–20 min before 12 am
Dagan et al., 2013 3 52 Male Bipolar Disorder type-I Asenapine 15 mg SW and SRE Asenapine discontinued Yes; immediately
daily Parasomnia
Amnesia of SW episode
51 Male Bipolar disorder type- I Quetiapine 600 mg SW, parasomnia Quetiapine discontinued Yes; immediately
daily
41 Male Bipolar disorder type- I Olanzapine 15 mg SW, parasomnia Olanzapine discontinued Yes; immediately
daily
Tamanna et al. 2012 2 51 Male MDD with Sleep Apnea Quetiapine 150 mg SW and SRE Quetiapine discontinued. Yes; in three
QHS Parasomnia CPAP started for sleep apnea. months
Amnesia of SW episode
2–3 SW episodes at night
per week
50 Female MDD with Sleep Apnea Quetiapine 200 mg SW and SRE Quetiapine discontinued Yes; in three
QHS Amnesia of SW episode CPAP started for sleep apnea months
2–3 SW episodes at night
per week
Raja et al. 2013 4 59 Female Bipolar Disorder type-II Quetiapine 50 mg SW Quetiapine tapered to 25 mg Yes; immediately
with insomnia QHS Akathisia QHS
Confusion
Recall was vague
37 Male Bipolar Disorder type-II Quetiapine 50 mg SW and SRE Quetiapine discontinued Yes; immediately
with QHS Confusion
insomnia
53 Male Bipolar Disorder type-II Quetiapine 300 mg SW No medication changes Yes; in six months
daily Parasomnia
Confusion
75 Female MDD with insomnia Quetiapine 25 mg Sleep talking No medication changes No
QHS Parasomnia
Sleep arousal
Confusion
Faridhosseini et al. 1 42 Male Schizophrenia Olanzapine 20 mg SW Olanzapine tapered to 15 mg Yes, in six months
2012 daily Sleep talking daily.
Parasomnia Started Clonazepam 1 mg QHS
Amnesia of SW episode
Heathman et al. 1 48 Female Bipolar Disorder type- I Quetiapine SW and SRE Quetiapine discontinued Yes; immediately
2014 100 mg QHS
Chiu YH, et al. 2008 1 52 Male Bipolar Disorder type- II Olanzapine 20 mg SW Olanzapine discontinued Yes; immediately
daily Parasomnia
Episode within 2–3 h of
sleep
Amnesia of SW episode
Hafeez et al. 2007 2 52 Male Schizoaffective Disorder Quetiapine 200 mg SW and SRE Quetiapine tapered to 25 mg Yes; in eight
QHS Leg jerks QHS months
Parasomnia Started Clonazepam 1 mg QHS
Amnesia of SW episode
18 Male ADHD with PDD Quetiapine 400 mg Nightmares with Quetiapine tapered to 150 mg Yes, in one year
QHS shouting QHS
Parasomnia
Seeman et al. 2011 1 50 Female Schizophrenia Quetiapine 900 mg SW and SRE Quetiapine 900 mg QHS Yes; immediately
QHS Parasomnia continued with Clonazepam 2
Amnesia of SW episode mg QHS
Kolivakis et al. 2001 2 63 Male Schizophrenia Olanzapine 20 mg SW Olanzapine switched to Yes; in six months
daily Risperidone
62 Female Schizophrenia Olanzapine 20 mg SW Olanzapine switched to Yes; in three
QHS Risperidone months
Lu et al. 2004 1 68 Male Psychosis disorder Risperidone 2 mg SW and SRE Risperidone tapered to 1 mg Yes; immediately
daily Parasomnia daily
Amnesia of SW episode
Paquet et al. 2004 1 52 Male Bipolar disorder type- I Olanzapine 20 mg SW and SRE Olanzapine discontinued Yes; immediately
with MDD daily Parasomnia
Amnesia of SW episode
Gunes et al. 2016 1 16 Female Conduct disorder Risperidone 1 mg SW and SRE 2–3 times Risperidone tapered to 0.5 mg Yes; in one month
daily per week daily with no improvement.
Parasomnia Risperidone discontinued
(continued on next page)

78

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

Table 2 (continued)

Study N Age (years) Gender Diagnosis Antipsychotic Clinical Characteristics Treatment Remission

Weight gain of 6.5 kg in


one month
Amnesia of SW episode
Najmi et al. 2020 1 38 Male Schizophrenia Risperidone 3 mg SW, parasomnia Tapered risperidone 2 mg Yes; in three
daily Amnesia of SW episode daily months
Started clonazepam 0.5 mg at
nigh time

Abbreviations: SW: Sleep Walking; SRE: Sleep-related eating; CPAP: Continuous Positive Airway Pressure; MDD: Major Depressive Disorder; ADHD: Attention-deficit/
hyperactivity disorder; PDD: Pervasive Developmental Disorder.

increasingly prescribed for both FDA-approved and off-label indications association with SRE are still unclear. This may be related to atypical
for a range of psychiatric and medical conditions. SW and SRE are antipsychotics effect on 5HT-2C receptor which regulates mood, an-
complex sleep-related behaviors that can lead to significant risks in- xiety, feeding, and reproductive behavior [65]. So, 5HT-2C antagonism
cluding patient safety and cause side effects such as weight gain and by atypical antipsychotics increases appetite and food intake and leads
metabolic dysfunction. to weight gain [66]. There is a significant association between elevated
Adult-onset SW is a relatively infrequent phenomenon; however, it leptin level and weight gain in patients on antipsychotics [67]. Altered
has been reported in higher proportion in psychiatric populations. serotonin activity, 5-HT2C receptor blockade with resultant enhance-
Additionally, adult-onset sleepwalkers have been noted to have higher ment of slow wave sleep (SWS) or NREM stage N3 sleep, increase in
peak frequency of SW behaviors and a high comorbidity with sleep- appetite, 5-HT2A blockade with resultant withdrawal of motor inhibi-
related eating features [58]. Komada and colleagues reported compared tion during SWS, and induction of partial arousals during SWS resulting
clinical features of drug-induced SRE higher mean age of onset and from atypical antipsychotic medication therapy have been cited as
significantly lower rate of history of sleepwalking in patients taking underlying mechanisms of SRE [25].
sedative drugs (benzodiazepines/benzodiazepine receptor agonists), as Upon review of the receptor profiles and mechanism of action of
compared to those with primary SRE (non-drug induced) [59]. Our data various atypical antipsychotics, it is evident that quetiapine, olanza-
resembles these prior findings in terms of higher mean age of onset of pine, risperidone, ziprasidone and asenapine have a high degree of
SW/SRE behaviors and lower history of SW in patients with SW/SRE histamine (H1) receptor affinity. H1 receptor blockade can result in
associated with atypical antipsychotic use. Primary SRE has been de- sedation, increased appetite and increased PLMs (resulting in partial
scribed mainly in females by Schenck and Mahowald [60]; however, arousals during NREM sleep) [25]. Quetiapine and olanzapine are
our preliminary findings suggest that SRE associated with atypical an- among the most potent H1 antagonists in the category of atypical an-
tipsychotics is reportedly more common in males. tipsychotics. It is plausible that H1 antagonism may also offer the ex-
SW is an arousal disorder occurring in NREM sleep characterized by planation for quetiapine and olanzapine being the most commonly
complex behaviors such as leaving the bed and walking along with implicated among atypical antipsychotics in causation of SW and SRE.
memory impairment of the event. The underlying mechanisms for this Atypical antipsychotics are also known to precipitate restless legs syn-
phenomenon remain unclear, although, the disordered arousal has been drome (RLS) [68] which may further predispose patients taking these
largely attributed to an inability of the brain to fully awaken from slow- medications to SW and SRE. RLS is a condition that needs particular
wave sleep (SWS) followed by the motor automatisms characteristic of attention in the context of both SW and SRE as motor restlessness un-
SW [61]. Based on a neuroimaging study, as compared to healthy derlying RLS may compel an individual to ambulate during sleep and
subjects, reduction in regional cerebral perfusion frontal and parietal engage in unconscious or partly conscious eating [69,70]. Furthermore,
areas has been reported in sleep walkers; and these regions have been frequent periodic limb movements of sleep (PLMS) which are seen in
previously associated with slow wave sleep (SWS) generation and SW 80% to 90% of patients with RLS can cause partial arousals during SWS
episode occurrence [62]. Polysomnography (PSG) findings in patients and result in SW with or without SRE. Dopaminergic blockade by aty-
with SRE show a correlation with sleep-walking with states of arousal pical antipsychotics has been conceptualized as the likely mechanism to
leading to occurrence of SRE, mostly in SWS, in the affected individuals cause RLS. Although not well studied, H1 receptor blockade by atypical
[63]. antipsychotics may be another relevant mechanism to consider for RLS
Quetiapine and other atypical antipsychotics block 5-hydro- causation/exacerbation as antihistaminic medications such as di-
xytryptamine-2A (5HT-2A) and dopamine receptors subtype 2 (D2) and phenhydramine have been implicated in causation/exacerbation of RLS
increase cortical dopamine release by 5HT-1A agonism [25]. Among all symptoms [71].
serotonergic receptors, 5HT-2A receptors in the dorsal raphe nucleus SW associated with atypical antipsychotics may respond to the
regulate frequency and amplitude of slow wave sleep (SWS) [64]. These discontinuation of the offending agent. SW with SRE related to other
serotonergic neurons maintain the hypotonia of the antigravity muscles primary sleep disorders benefit most from the treatment of the under-
during SWS. Normally, maintenance of SWS is synchronized with motor lying primary sleep disorder. For example, RLS-related SW with SRE is
inhibition such that there is no motor activity without an arousal [44]. best treated with dopamine agonists such as pramipexole [72]. For
A blockade of serotonergic input leads to withdrawal of motor inhibi- patients with comorbid OSA, optimal treatment of OSA symptoms can
tion, allowing the person to walk and perform other motor activities be effective in resolving SRE [44]. SW with SRE may respond to
[44]. Therefore, it is plausible that atypical antipsychotics, due to treatment with low-dose benzodiazepines, such as clonazepam [73].
blockade of 5-HT serotonergic receptors with resultant alteration of Treatment of idiopathic SRE includes SSRIs, topiramate and benzodia-
central serotonin activity, can lead to SW without a complete arousal zepines such as clonazepam [74]. Topiramate has also been found to be
[44]. effective in patients with SRE, with one study demonstrating im-
SW aggravated by atypical antipsychotics may be explained by the provement or resolution of sleep related eating [73].
above hypothesis [44]; however, the mechanisms underlying its The main limitation of our study is inclusion of just anecdotal

79

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

literature focusing on association of SW, with or without SRE, and Washington, DC: American Psychiatric Association; 2013.
atypical antipsychotic use in psychiatric patients. The single case re- [2] Malhotra RK, Avidan AY. Parasomnias and their mimics. Neurol Clin
2012;30:1067–94.
ports or case series are useful for providing hypotheses about behavior [3] Ohayon MM, Guilleminault C, Priest RG. Night terrors, sleepwalking, and confu-
and opportunities for clinical innovation, permitting intensive study of sional arousals in the general population: their frequency and relationship to other
rare ADRs, challenging theoretical assumptions and coming up with sleep and mental disorders. J Clin Psychiatry 1999;60:268–76. [quiz 277].
[4] Stallman HM, Kohler M. Prevalence of sleepwalking: a systematic review and meta-
new putative mechanisms but they do not necessarily demonstrate analysis. PLoS One 2016;11:e0164769.
causation [75]. The long term follow-up of the majority of the un- [5] Laberge L, Tremblay RE, Vitaro F, Montplaisir J. Development of parasomnias from
published cases in our clinics does support the fact that the episodes of childhood to early adolescence. Pediatrics 2000;106:67–74.
[6] Mahowald MW, Cramer Bornemann MA. Non-REM arousal parasomnias. Non-REM
SW/SRE were associated with atypical antipsychotic use as these arousal parasomnias principles and practice of sleep medicine. 5th ed. St. Louis:
parasomnia behaviors did not recur after appropriate clinical manage- Elsevier Saunders; 2011. (1175–1082).
ment as detailed in this paper. However, the role of psychotropic [7] International classification of sleep disorders, diagnostic and coding manual. 2nd
ed. Westchester, IL: American Academy of Sleep Medicine; 2014.
polypharmacy cannot be ruled out completely in causation of such
[8] Pressman MR. Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med
behaviors in psychiatric patients taking complex psychotropic regi- Rev 2011;15:285–92.
mens. [9] Zolpidem: sleepwalking and automatic behaviours. Prescrire Int 2007;16:200.
Our study does have important clinical implications as it highlights [10] Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpi-
dem—sleepwalking: a case report. Arch Phys Med Rehabil 2005;86:1265–6.
the need for clinicians to consider SW and SRE as potential ADRs of [11] Iruela LM. Zolpidem and sleepwalking. J Clin Psychopharmacol 1995;15:223.
atypical antipsychotic therapy, particularly in the context of weight [12] Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol
gain from use of this class of medications. Patient education along with 1994;14:150.
[13] Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex
early recognition and management of SW with SRE can prevent harmful behavior. J Am Acad Child Adolesc Psychiatry 2004;43:927–8.
consequences such as injury, weight gain and metabolic dysfunction. [14] Chen YW, Tseng PT, Wu CK, Chen CC. Zaleplon-induced anemsic somnambulism
The mechanisms underlying SW and SRE in context of atypical anti- with eating behaviors under once dose. Acta Neurol Taiwan 2014;23:143–5.
[15] Ferentinos P, Paparrigopoulos T. Zopiclone and sleepwalking. Int J
psychotic use are poorly understood. The etiology of this rare phe- Neuropsychopharmacol 2009;12:141–2.
nomenon is likely multifactorial and further research studies are war- [16] Ferrandiz-Santos JA, Mataix-Sanjuan AL. Amitriptyline and somnambulism. Ann
ranted to determine patient risk factors, underlying neurobiological Pharmacother 2000;34:1208.
[17] AOY Alao, Aumenta JC, W.C., Dewan MJ. Somnambulism precipitated by selective
mechanisms and optimal treatment strategies. serotonin-reuptake inhibitors. vol. 15. 1999. p. 204–7.
[18] Yilmaz U, Tatlisen A, Turan H, Arman F, Ekmekcioglu O. The effects of fluoxetine
5. Conclusions on several neurophysiological variables in patients with premature ejaculation. J
Urol 1999;161:107–11.
[19] Yeh YW, Chen CH, Feng HM, Wang SC, Kuo SC, Chen CK. New onset somnambulism
SW with or without SRE can be potentially disabling side effects associated with different dosage of mirtazapine: a case report. Clin Neuropharmacol
associated with atypical antipsychotic use. Prompt recognition of these 2009;32:232–3.
adverse side effects can prevent injury and metabolic side effects such [20] Kunzel HE, Schuld A, Pollmacher T. Sleepwalking associated with reboxetine in a
young female patient with major depression—a case report. Pharmacopsychiatry
as weight gain and metabolic dysfunction. Sleep evaluation is helpful to 2004;37:307–8.
rule out comorbid primary sleep disorders including obstructive sleep [21] Oulis P, Kokras N, Papadimitriou GN, Masdrakis VG. Bupropion-induced sleep-
apnea and restless legs syndrome. Discontinuation of the causative walking. J Clin Psychopharmacol 2010;30:83–4.
[22] Charney DS, Kales A, Soldatos CR, Nelson JC. Somnambulistic-like episodes sec-
atypical antipsychotic medication often leads to complete resolution of ondary to combined lithium-neuroleptic treatment. Br J Psychiatry
parasomnia behaviors. More research is warranted to elucidate the 1979;135:418–24.
mechanisms underlying SW and SRE associated with atypical anti- [23] Landry P, Montplaisir J. Lithium-induced somnambulism. Can J Psychiatry
1998;43:957–8.
psychotic use and to develop prevention and treatment strategies. [24] Landry P, Warnes H, Nielsen T, Montplaisir J. Somnambulistic-like behaviour in
patients attending a lithium clinic. Int Clin Psychopharmacol 1999;14:173–5.
Acknowledgments [25] Seeman MV. Sleepwalking, a possible side effect of antipsychotic medication.
Psychiatry Q 2011;82:59–67.
[26] Huapaya LV. Seven cases of somnambulism induced by drugs. Am J Psychiatry
None. 1979;136:985–6.
[27] Luchins DJ, Sherwood PM, Gillin JC, Mendelson WB, Wyatt RJ. Filicide during
psychotropic-induced somnambulism: a case report. Am J Psychiatry
Compliance with ethical standards
1978;135:1404–5.
[28] Deng S, Hu J, Zhu X, Shang D, Wen Y, Qiu C. Sleepwalking is associated with
Our review was conducted on published studies and did not contain coadministration of olanzapine and propranolol: a case report. J Clin
patient identifiable information. So, our study does not require an in- Psychopharmacol 2017;37:622–3.
[29] Huynh NT, Huot P. Propranolol-induced somnambulism: a case-report in a patient
stitutional review board (IRB) approval. with essential tremor. Can J Neurol Sci 2014;41:787–8.
[30] Pradalier A, Giroud M, Dry J. Somnambulism, migraine and propranolol. Headache
Disclosures 1987;27:143–5.
[31] Wei Y, Zhang Y, Lin Z, Wu S. Sleepwalking associated with metoprolol: a case re-
port. J Clin Psychopharmacol 2014;34:405–7.
On behalf of all authors, the corresponding author states that there [32] Hensel J, Pillmann F. Late-life somnambulism after therapy with metoprolol. Clin
is no conflict of interest. Neuropharmacol 2008;31:248–50.
[33] von Vigier RO, Vella S, Bianchetti MG. Agitated sleepwalking with fluoroquinolone
therapy. Pediatr Infect Dis J 1999;18:484–5.
Funding sources [34] Tessitore A, Giannetti LM, Manfellotto G. Somnambulism as a result of dopami-
nomimetics? Acta Neurol (Napoli) 1986;8:422–7.
[35] Arguz-Cildir D, Sahbudak B, Ozyurt G, Akay-Pekcanlar A. Somnambulism induced
The authors report no external funding source for this study.
by methylphenidate. Klin Psikofarmakol Bul 2014;24:S282–3.
[36] Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al.
Appendix A. Supplementary data Safety and efficacy of suvorexant during 1-year treatment of insomnia with sub-
sequent abrupt treatment discontinuation: a phase 3 randomised, double-blind,
placebo-controlled trial. Lancet Neurol 2014;13:461–71.
Supplementary data to this article can be found online at https:// [37] Xyrem International Study G. Further evidence supporting the use of sodium oxy-
doi.org/10.1016/j.genhosppsych.2020.05.014. bate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228
patients. Sleep Med 2005;6:415–21.
[38] Savage RL, Zekarias A, Caduff-Janosa P. Varenicline and abnormal sleep related
References events. Sleep 2015;38:833–7.
[39] Alkhuja S, Gazizov N, Alexander ME. Sleeptalking! Sleepwalking! Side effects of
[1] Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5. montelukast. Case Rep Pulmonol 2013;2013(8):13786.

80

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
A. Chopra, et al. General Hospital Psychiatry 65 (2020) 74–81

[40] Bjorvatn B, Gronli J, Pallesen S. Prevalence of different parasomnias in the general [59] Komada Y, Takaesu Y, Matsui K, Nakamura M, Nishida S, Kanno M, et al.
population. Sleep Med 2010;11:1031–4. Comparison of clinical features between primary and drug-induced sleep-related
[41] Waters F, Moretto U, Dang-Vu TT. Psychiatric illness and parasomnias: a systematic eating disorder. Neuropsychiatr Dis Treat 2016;12:1275–80.
review. Curr Psychiatry Rep 2017;19:37. [60] Schenck CH, Mahowald MW. Review of nocturnal sleep-related eating disorders. Int
[42] Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, Fuste AC, et al. J Eat Disorder 1994;15:343–56.
International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur [61] Plazzi G, Vetrugno R, Provini F, Montagna P. Sleepwalking and other ambulatory
Neuropsychopharmacol 2017;27:1064–76. behaviours during sleep. Neurol Sci 2005;26(Suppl. 3):s193–8.
[43] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. [62] Desjardins ME, Baril AA, Soucy JP, Dang-Vu TT, Desautels A, Petit D, et al. Altered
Head-to-head comparisons of metabolic side effects of second generation anti- brain perfusion patterns in wakefulness and slow-wave sleep in sleepwalkers. Sleep
psychotics in the treatment of schizophrenia: a systematic review and meta-ana- 2018;41.
lysis. Schizophr Res 2010;123:225–33. [63] Brion A, Flamand M, Oudiette D, Voillery D, Golmard JL, Arnulf I. Sleep-related
[44] Tamanna S, Ullah MI, Pope CR, Holloman G, Koch CA. Quetiapine-induced sleep- eating disorder versus sleepwalking: a controlled study. Sleep Med
related eating disorder-like behavior: a case series. J Med Case Reports 2012;6:380. 2012;13:1094–101.
[45] Raja M, Raja S. Sleepwalking in four patients treated with quetiapine. Psychiatr [64] Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, ilo-
Danub 2013;25:80–3. peridone, and melperone, preferentially increase dopamine and acetylcholine re-
[46] Heathman JC, Neal DW, Thomas CR. Sleep-related eating disorder associated with lease in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res
quetiapine. J Clin Psychopharmacol 2014;34:658–60. 2002;956:349–57.
[47] Hafeez ZH, Kalinowski CM. Two cases of somnambulism induced by quetiapine. [65] Puig MV, Watakabe A, Ushimaru M, Yamamori T, Kawaguchi Y. Serotonin mod-
Prim Care Companion J Clin Psychiatry 2007;9:313. ulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex
[48] Dagan Y, Katz G. A case of atypical antipsychotic-induced somnambulism: a class through 5-HT1A and 5-HT2A receptors. J Neurosci 2010;30:2211–22.
effect. J Clin Psychiatry 2013;74:370. [66] Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH. Serotonin 5-HT(2C) receptors reg-
[49] Paquet V, Strul J, Servais L, Pelc I, Fossion P. Sleep-related eating disorder induced ulate anxiety-like behavior. Genes Brain Behav 2007;6:491–6.
by olanzapine. J Clin Psychiatry 2002;63:597. [67] Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia
[50] Chiu YH, Chen CH, Shen WW. Somnambulism secondary to olanzapine treatment in and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat
one patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry Med 1998;4:1152–6.
2008;32:581–2. [68] Aggarwal S, Dodd S, Berk M. Restless leg syndrome associated with atypical anti-
[51] Faridhosseini F, Zamani A. A case report of somnambulism associated with olan- psychotics: current status, pathophysiology, and clinical implications. Curr Drug Saf
zapine. Iran J Psychiatry Behav Sci 2012;6:72–4. 2015;10:98–105.
[52] Das S, Gupta R, Dhyani M, Sah D, Maity J. Role of 5HT1A and 5HT2A receptors and [69] Howell M. Darwin's predisposition and the restlessness that drives sleepwalking.
default mode network in olanzapine-induced somnambulism. Neurol India Sleep 2015;38:1667–8.
2017;65:373–4. [70] Howell MJ. Restless eating, restless legs, and sleep related eating disorder. Curr
[53] Kolivakis TT, Margolese HC, Beauclair L, Chouinard G. Olanzapine-induced som- Obes Rep 2014;3:108–13.
nambulism. Am J Psychiatry 2001;158:1158. [71] Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome.
[54] Gunes S, Camkurt MA. Sleep-related eating disorder associated with risperidone: an Neurotherapeutics 2012;9:776–90.
adolescent case. J Clin Psychopharmacol 2016;36:286–8. [72] Kobayashi N, Yoshimura R, Takano M. Successful treatment with clonazepam and
[55] Najmi A, Siddiqui F, Ray A, Jhaj R, Sadasivam B. Risperidone-induced somnam- pramipexole of a patient with sleep-related eating disorder associated with restless
bulism: a case report and brief review of literature. Cureus 2020;12:e7238. legs syndrome: a case report. Case Rep Med 2012;2012:893681.
[56] Lu ML, Shen WW. Sleep-related eating disorder induced by risperidone. J Clin [73] Chiaro G, Caletti MT, Provini F. Treatment of sleep-related eating disorder. Curr
Psychiatry 2004;65:273–4. Treat Options Neurol 2015;17:361.
[57] Das P. A case of sleepwalking with sleep-related eating associated with ziprasidone [74] Auger RR. Sleep-related eating disorders. Psychiatry (Edgmont) 2006;3:64–70.
therapy in a patient with schizoaffective disorder. J Clin Psychopharmacol [75] Stallman HM, Kohler M, White J. Medication induced sleepwalking: a systematic
2016;36:393–4. review. Sleep Med Rev 2018;37:105–13.
[58] Lam S-P, Fong SY-Y, Yu MW-M, Li SX, Wing Y-K. Sleepwalking in psychiatric pa- [76] Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred
tients: comparison of childhood and adult onset. Aust N Z J Psychiatry Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009;43:426–30. PLoS Med 2009;6(7):e1000097https://doi.org/10.1371/journal.pmed1000097.

81

Downloaded for Anonymous User (n/a) at Far Eastern University Doctor Nicanor Reyes Medical Foundation from ClinicalKey.com by Elsevier on October 25, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.

You might also like